Medexus Pharmaceuticals Inc Statistics
Want to see TSE:MDP full AI Analyst Report?
Medexus Pharmaceuticals Inc (MDP) Stock Statistics & Valuation Metrics
Total Valuation
Medexus Pharmaceuticals Inc has a market cap or net worth of CAD 162.79M. The enterprise value is CAD 192.00M.
- Market Cap
- CAD 162.79M
- Enterprise Value
- CAD 192.00M
Share Statistics
Medexus Pharmaceuticals Inc has 31,425,983 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 31,425,983
- Owned by Insiders
- 8.12%
- Owned by Institutions
- 2.36%
Financial Efficiency
Medexus Pharmaceuticals Inc’s return on equity (ROE) is -0.05 and return on invested capital (ROIC) is 6.08%.
- Return on Equity (ROE)
- -0.05
- Return on Assets (ROA)
- -0.02
- Return on Invested Capital (ROIC)
- 6.08%
- Return on Capital Employed (ROCE)
- 0.06
- Revenue Per Employee
- 1.10M
- Profits Per Employee
- -26.60K
- Employee Count
- 90
- Asset Turnover
- 0.67
- Inventory Turnover
- 1.35
Valuation Ratios
The current PE Ratio of Medexus Pharmaceuticals Inc is -48.83. Medexus Pharmaceuticals Inc’s PEG ratio is -0.59.
- PE Ratio
- -48.83
- PS Ratio
- 1.13
- PB Ratio
- 2.47
- Price to FCF
- -96.63
- Price to Operating Cash Flow
- 8.57
- PEG Ratio
- -0.59
Income Statement
In the last 12 months, Medexus Pharmaceuticals Inc had revenue of 99.33M and earned -2.39M in profits. Earnings per share was -0.07.
- Revenue
- 99.33M
- Gross Profit
- 54.41M
- Operating Income
- 5.83M
- Pretax Income
- -2.27M
- Net Income
- -2.39M
- EBITDA
- 12.66M
- Earnings Per Share (EPS)
- -0.07
Cash Flow
In the last 12 months, operating cash flow was 13.84M and capital expenditures -15.05M, giving a free cash flow of -1.21M billion.
- Operating Cash Flow
- 13.84M
- Free Cash Flow
- -1.21M
- Free Cash Flow per Share
- -0.04
Dividends & Yields
Medexus Pharmaceuticals Inc pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -1.03%
- Earnings Yield
- -1.99%
Stock Price Statistics
- Beta
- 1.27
- 52-Week Price Change
- 98.13%
- 50-Day Moving Average
- 4.99
- 200-Day Moving Average
- 4.25
- Relative Strength Index (RSI)
- 62.81
- Average Volume (3m)
- 37.49K
Important Dates
Medexus Pharmaceuticals Inc upcoming earnings date is Feb 10, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 11, 2026
- Next Earnings Date
- Feb 10, 2027
- Ex-Dividend Date
- ―
Financial Position
Medexus Pharmaceuticals Inc as a current ratio of 1.19, with Debt / Equity ratio of 45.45%
- Current Ratio
- 1.19
- Quick Ratio
- 0.57
- Debt to Market Cap
- 0.22
- Net Debt to EBITDA
- 1.24
- Interest Coverage Ratio
- 1.12
Taxes
In the past 12 months, Medexus Pharmaceuticals Inc has paid 120.00K in taxes.
- Income Tax
- 120.00K
- Effective Tax Rate
- -0.05
Enterprise Valuation
Medexus Pharmaceuticals Inc EV to EBITDA ratio is 10.91, with an EV/FCF ratio of -113.88.
- EV to Sales
- 1.34
- EV to EBITDA
- 10.91
- EV to Free Cash Flow
- -113.88
- EV to Operating Cash Flow
- 9.97
Balance Sheet
Medexus Pharmaceuticals Inc has CAD 5.34M in cash and marketable securities with CAD 26.21M in debt, giving a net cash position of -CAD 20.88M billion.
- Cash & Marketable Securities
- CAD 5.34M
- Total Debt
- CAD 26.21M
- Net Cash
- -CAD 20.88M
- Net Cash Per Share
- -CAD 0.66
- Tangible Book Value Per Share
- -CAD 0.75
Margins
Gross margin is 54.73%, with operating margin of 6.64%, and net profit margin of -2.29%.
- Gross Margin
- 54.73%
- Operating Margin
- 6.64%
- Pretax Margin
- -2.31%
- Net Profit Margin
- -2.29%
- EBITDA Margin
- 12.24%
- EBIT Margin
- 2.83%
Analyst Forecast
The average price target for Medexus Pharmaceuticals Inc is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -3.16%
- EPS Growth Forecast
- -345.50%
Scores
- Smart Score
- 7
- AI Score
- 60
